Background: Preliminary evidence indicates that prophylactic-dose thromboprophylaxis may
be inadequate to control the increased risk of venous thromboembolism (VTE) in patients …

Abstract The 2019 coronavirus disease (COVID-19) presents with a large variety of clinical
manifestations ranging from asymptomatic carrier state to severe respiratory distress …

Importance Hospitalized patients with COVID-19 are at risk for venous and arterial
thromboembolism and death. Optimal thromboprophylaxis dosing in high-risk patients is …

2 METHODS This guidance statement is a collaborative effort of the Perioperative and
Critical Care Thrombosis and Haemostasis Subcommittee, along with members of the …

Abstract Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with
a high incidence of thrombotic events during hospitalization; however, data examining rates …

Thromboembolic events, including venous thromboembolism (VTE) and arterial
thromboembolism (ATE), and mortality from subclinical thrombotic events occur frequently in …

At the end of last year, a novel coronavirus, severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2), resulted in an acute respiratory illness epidemic in Wuhan, China [1, 2] …

COVID-19 has proven to be particularly challenging given the complex pathogenesis of
SARS-CoV-2. Early data have demonstrated how the host response to this novel …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to a worldwide
pandemic, and patients with the infection are referred to as having COVID‐19. Although …

Abstract Introduction Coronavirus disease (COVID‐19) is associated with a high incidence
of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is …